• Around 200 healthcare professionals attended the event, reflecting strong interest in AI-enabled preventive healthcare solutions.
  • Experts from MIT Jameel Clinic, the National Cancer Center Hospital, and Yotsuya Medical Cube shared insights on advanced cancer risk prediction technologies and their potential application in Japan.

Nagoya, Japan: Jameel Corporation, based in Japan and part of Abdul Latif Jameel, a network of internationally diversified businesses, co-hosted a luncheon seminar on “The Future of Preventive Medicine Powered by AI — From ‘Detecting Disease’ to ‘Preventing Disease’” at the 28th Annual Meeting of the Japan Society for Health Care Management. The seminar was held in Japan with support from MIT Jameel Clinic, the epicenter of artificial intelligence and health at the Massachusetts Institute of Technology (MIT) established in partnership with Community Jameel, an international organization advancing science and learning for communities to thrive.

Approximately 200 healthcare professionals attended the seminar, reflecting strong interest in preventive medicine and the application of AI in healthcare. The seminar was chaired by Dr. Toshiki Mano, Professor at the Graduate School of Strategic Management, Chuo University, and featured presentations by Dr. Mitsuhiro Hayashi, Director of the Department of Breast Surgery at Yotsuya Medical Cube; Dr. Nacer Mami, Regional Lead – Clinical Network, MIT Jameel Clinic; and Dr. Ayumi Saito of the Department of Medical Oncology at the National Cancer Center Hospital in Japan.

Centered on the theme of transitioning from “detecting and treating disease” to “predicting and preventing disease,” the presentations introduced MIT Jameel Clinic’s AI-based cancer risk prediction models MIRAI and SYBIL. MIRAI predicts the risk of developing breast cancer up to five years in advance from a patient’s mammogram, while SYBIL, predicts the risk of developing lung cancer up to six years in advance from a patient’s low-dose CT scan.

The speakers emphasized the importance of generating evidence based on Japanese patient data. Based on ongoing collaborative research with the National Cancer Center Hospital and Yotsuya Medical Cube, they also discussed the opportunities and challenges for the social implementation of MIRAI and SYBIL in Japan.

The seminar provided an important opportunity to share the potential of AI-enabled predictive medicine and personalized preventive medicine, marking a significant step toward realizing “preventing disease” in Japan.

About Abdul Latif Jameel:

Abdul Latif Jameel is an over 80-year-old network of internationally diversified businesses shaping the future of its core sectors: mobility, energy & water, financial services, investments and health, with a strong commitment to continuous investment in people, business, technology, and community. The network spans more than 35 countries and employs over 11,000 people representing more than 80 nationalities.

For more information, please visit https://alj.com/en/.

Copyright Notice & Disclaimer

Abdul Latif Jameel © All rights reserved.  The “Abdul Latif Jameel” name and the “Abdul Latif Jameel” logotype and pentagon-shaped graphics are trademarks or registered trademarks.

Data:

The information presented in this document is intended for general informational purposes only. Any numerical data provided is accurate as of June 2026 but may not be updated in real-time and becomes outdated over time.  While every effort has been made to ensure the accuracy and reliability of the information provided, Abdul Latif Jameel makes no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability, or availability with respect to the content contained herein.

Any references made to the content of this document are for demonstration and discussion purposes, and do not imply any legal ownership or affiliation unless explicitly stated otherwise. Any actual transactions or agreements concerning the content of this presentation would require separate legal documentation and due diligence.

Reliance on the information provided is strictly at your own risk. Abdul Latif Jameel disclaims any liability for any loss or damage, including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this numerical data and the information contained within this presentation.

Forward Looking Statements

This presentation may contain forward-looking statements.  Forward-looking statements are statements regarding matters other than historical fact, such as future results, events, activities, developments or circumstances or the beliefs, plans or expectations of Abdul Latif Jameel entities or their respective managements.  Forward-looking statements often can be identified by the use of words such as ‘expect’, ‘project’, ‘anticipate’, ‘plan’, ‘estimate’, ‘believe’, ‘predict’, ‘intend’, ‘potential’, ‘possible’, ‘probable’, ‘likely’, ‘forecast’, ‘guidance’, ‘outlook’, ‘goal’, ‘target’, ‘may’, ‘will’, ‘should’ or ‘could’ or other similar terms or phrases.  However, the absence of such words does not mean that a particular statement is not forward looking.

Forward-looking statements are based on expectations and assumptions at the time of such statements and are subject to numerous risks and uncertainties, many of which are outside the control of the Abdul Latif Jameel entities.  Should any of such expectations or assumptions prove incorrect, or should any of such risks or uncertainties materialize, actual future results, events, activities, developments or circumstances may differ materially from those expressed in or implied by forward-looking statements.  Further, any forward-looking statement speaks only as of the date on which it is made, and Abdul Latif Jameel does not assume, and hereby disclaim, any obligation to correct or update any forward-looking statement, whether as a result of new information, future events or otherwise.

All forward-looking statements made by Abdul Latif Jameel or by any person on behalf of it, whether communicated in writing, electronically orally, are qualified in their entirety by the foregoing cautionary statements. 

No Offer or Solicitation

This communication is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential transaction and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.  No offering of securities shall be made except by means of a prospectus meeting the requirements of applicable laws, or an exemption therefrom.